Did Drake confirm using Ozempic?

Yes. Drake confirmed Ozempic use through social media posts in 2023. He discussed it casually, without framing it as a medical disclosure. Whether he continues to use the medication has not been publicly stated.

What happens when you stop taking Ozempic?

Clinical trial data from the STEP 1 extension showed that patients regained approximately two-thirds of lost weight within one year of discontinuation. Appetite suppression, metabolic benefits, and cardiometabolic improvements also partially reversed. This pattern is consistent across GLP-1 receptor agonist studies.

Is Ozempic meant to be taken forever?

The FDA has not specified a maximum treatment duration. Clinical guidelines from the American Diabetes Association and obesity medicine specialists increasingly treat GLP-1 therapy as chronic management rather than a time-limited course. The decision to continue, reduce dose, or stop should be individualized with a prescribing physician.

Does Ozempic cause muscle loss?

Semaglutide-associated weight loss includes a lean mass component. Some analyses suggest up to 40% of weight lost may be lean tissue. Resistance training and adequate protein intake (1.2 to 1.6 g/kg/day) during treatment can reduce but not eliminate this effect. Patients should discuss body composition monitoring with their provider.

Can you taper off Ozempic instead of stopping suddenly?

No FDA-approved tapering protocol exists. Some clinicians step patients down gradually (e.g., 1 mg to 0.5 mg to 0.25 mg over weeks), but this strategy has not been validated in randomized trials. Regardless of approach, having a post-cessation maintenance plan is considered essential.

Drake, Maintenance, and What Happens If You Stop

By HealthRX Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

Drake's Public Confirmation

In 2023, Drake acknowledged using Ozempic through social media posts, making him one of the most prominent male public figures to openly confirm GLP-1 receptor agonist use. His candor stood out. At the time, celebrity GLP-1 discourse skewed heavily toward women, and male use remained something most public figures avoided discussing.

Between 2022 and 2024, mainstream media outlets documented visible changes in Drake's body composition. He appeared notably leaner in concert footage and public appearances covered by outlets including TMZ and People. The HealthRX Medical Team notes that these observations align with expected semaglutide outcomes, though the specific details of Drake's dosing, duration, or current status remain his private medical information.

What Drake has not publicly confirmed: whether he is still taking Ozempic, whether he transitioned to a different GLP-1 medication, or whether he discontinued treatment. That distinction matters clinically, because the question of what happens after stopping a GLP-1 agonist is one of the most consequential in obesity medicine right now.

At a glance

Celebrity: Drake (Aubrey Drake Graham)
Drug: Ozempic (semaglutide 0.5 mg, 1 mg, or 2 mg weekly injection)
Drug class: GLP-1 receptor agonist
Status: Confirmed use via 2023 social posts
Current use: Not publicly disclosed
Clinical focus of this page: Discontinuation outcomes, weight regain data, and maintenance strategies

How Semaglutide Works (and Why Stopping It Reverses Course)

Semaglutide mimics the incretin hormone GLP-1, binding to receptors in the pancreas, gut, and brain. In the hypothalamus, it suppresses appetite signaling. In the stomach, it slows gastric emptying. The net result: patients eat less, feel full sooner, and experience reduced food-focused reward signaling. A 2021 NEJM trial showed mean weight loss of 14.9% over 68 weeks at the 2.4 mg dose (marketed as Wegovy).

The critical detail is that semaglutide does not cure obesity. It manages it. The drug suppresses appetite through continuous receptor activation. When that activation stops, the biological drivers of weight gain, including elevated ghrelin, reduced satiety signaling, and metabolic adaptation, return. The hypothalamus does not "reset" to a new set point just because a patient spent a year at a lower weight.

This is not a failure of willpower. It is physiology. Research published in The Lancet has consistently shown that the body defends its highest sustained weight through hormonal and metabolic compensation, a process that persists for years after weight loss.

The STEP 1 Extension: What the Data Actually Shows

The most cited discontinuation data comes from the STEP 1 trial extension, published in Diabetes, Obesity and Metabolism in 2022. Participants who stopped semaglutide after 68 weeks regained approximately two-thirds of their lost weight within the following year. Cardiometabolic improvements in blood pressure, lipid profiles, and HbA1c also partially reversed.

The numbers are stark. Patients who lost an average of 17.3% of body weight regained roughly 11.6 percentage points of that loss by week 120. Only a fraction maintained clinically meaningful weight reduction (>5%) without the drug.

A separate analysis from the STEP 4 trial (JAMA, 2021) tested a different design: all participants received semaglutide for 20 weeks, then half were switched to placebo. The placebo group regained 6.9% of body weight over the next 48 weeks, while the continuation group lost an additional 7.9%. The divergence was immediate and sustained.

The HealthRX Medical Team's Clinical Read

The HealthRX Medical Team sees Drake's public confirmation as medically significant for one reason: it forced a conversation about GLP-1 medications as ongoing treatment rather than a short-term fix. Too many patients (and prescribers) still treat semaglutide like a course of antibiotics. Take it, lose weight, stop. The discontinuation data makes clear that this model fails the majority of patients.

For someone like Drake, who is in his late 30s, physically active, and presumably has access to comprehensive medical monitoring, the clinical calculus around continuation versus discontinuation involves several factors:

If continuing long-term, the considerations include injection site reactions over years of use, potential gallbladder complications (cholelithiasis risk increases with rapid weight loss), periodic monitoring of thyroid function given the boxed warning for medullary thyroid carcinoma in rodent models, and gastrointestinal tolerance.

If discontinued, the priority shifts to structured maintenance. The clinical literature supports three evidence-based strategies for post-GLP-1 weight maintenance: high protein intake (1.2 to 1.6 g/kg/day) to preserve lean mass, structured resistance training to counteract the lean-mass loss that accompanies GLP-1-mediated weight reduction, and close metabolic follow-up for 12 to 24 months post-cessation. A 2023 review in Obesity Reviews emphasized that patients who combine behavioral intervention with pharmacotherapy show better maintenance than those who relied on medication alone.

Lean Mass Loss: The Underreported Risk

One clinical concern the HealthRX Medical Team highlights is lean mass loss during GLP-1 treatment. Semaglutide produces weight loss that is roughly 60% fat and 40% lean tissue in some analyses, a ratio that is worse than what is typically seen with caloric restriction alone. A JAMA Network analysis noted that the proportion of lean mass lost during semaglutide treatment raises questions about long-term musculoskeletal health, particularly in patients who are not resistance training.

For a performer like Drake, whose career involves physically demanding concert tours, maintaining muscle mass and functional strength is not cosmetic. It is occupational. If he discontinued Ozempic without a structured resistance program, the combination of lean mass loss during treatment and fat regain afterward could leave him at a worse body composition than baseline. This phenomenon, sometimes called "fat overshooting," has been documented in post-diet rebound studies.

Dose Tapering: Clinical Practice vs. Label

Ozempic's prescribing information does not include a tapering protocol. The FDA label provides dose escalation guidance (0.25 mg for 4 weeks, then 0.5 mg, with optional increases to 1 mg or 2 mg) but says nothing about stepping down. In clinical practice, some prescribers taper patients gradually. Dropping from 1 mg to 0.5 mg to 0.25 mg over several weeks before stopping. The rationale is to reduce the abruptness of appetite signal restoration.

No randomized trial has validated tapering versus abrupt cessation. The HealthRX Medical Team considers it a reasonable but unproven strategy. What is proven: patients benefit from having a post-cessation plan in place before stopping, not after weight regain has already begun.

Why Drake's Openness Changed the Conversation

Before Drake's confirmation, GLP-1 discourse among male celebrities was almost nonexistent. Elon Musk had acknowledged using Wegovy, but within the entertainment industry, and particularly among Black male public figures, open discussion of weight-management medication carried stigma. Drake's casual, unapologetic confirmation through social media rather than a structured press interview signaled that GLP-1 use did not need to be treated as a confession.

The HealthRX Medical Team sees clinical value in this normalization. CDC data shows that obesity prevalence among Black men in the United States exceeds 40%. GLP-1 receptor agonists are among the most effective pharmacological tools available, yet prescribing rates remain lower in Black and Hispanic populations due to cost barriers, insurance coverage gaps, and cultural stigma. Public figures who openly discuss their use can reduce one of those barriers.

What Patients Should Take From This

Drake's situation, confirmed use with unknown continuation status, mirrors what millions of patients face. The GLP-1 decision is not a one-time choice. It is an ongoing calculation that balances efficacy, side effects, cost, and personal goals.

The clinical evidence is clear on three points. First, semaglutide works. Weight loss of 10% to 15% is reproducible in trials and real-world data. Second, stopping semaglutide leads to weight regain in the majority of patients. Third, long-term use appears safe based on available follow-up data, though the SELECT cardiovascular outcomes trial (NEJM, 2023) followed patients for a median of only 39.8 months.

The honest medical answer to "what happens if you stop?" is this: the weight will likely come back unless you have built a strong behavioral and metabolic foundation during treatment. That foundation includes dietary habits, exercise routines, sleep optimization, and stress management, none of which semaglutide provides on its own.

Frequently asked questions

›

References

Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. NEJM. 2021;384(11):989-1002. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes Obes Metab. 2022;24(8):1553-1564. https://pubmed.ncbi.nlm.nih.gov/35441470/
Rubino D, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance. JAMA. 2021;325(14):1414-1425. https://pubmed.ncbi.nlm.nih.gov/34706925/
Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. NEJM. 2023;389(24):2221-2232. https://pubmed.ncbi.nlm.nih.gov/37952131/
Ozempic (semaglutide) prescribing information. FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209637s009lbl.pdf
CDC Adult Obesity Facts. https://www.cdc.gov/obesity/data/adult.html